MacroGenics submits margetuximab BLA to the FDA

MacroGenics (NASDAQ:MGNX) submitted a biologics license application (BLA) for margetuximab for the treatment of patients with metastatic HER2-positive breast cancer. The submission is based on the safety and efficacy...

Season’s Greetings (and JPM 2020)

Wow, what an interesting year 2019 has turned out to be!On behalf of everyone at BioTuesdays, I would like to wish you all a safe and happy holiday season. After taking a short break to spend time with family and...


Sign up to our weekly BioTuesdays newsletter.